trending Market Intelligence /marketintelligence/en/news-insights/trending/oijaYM9bnQDiQV96TH7YLw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Lupin launches fungal infection tablets, oral suspension in US

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Lupin launches fungal infection tablets, oral suspension in US

India's Lupin Ltd. announced the U.S. launch of Voriconazole to treat fungal infections in patients 12 years old and above.

The U.S.-FDA approved generic was launched in 50 mg and 200 mg tablets and 40 mg/ml oral suspension. Voriconazole will compete with PF Prism CV's Vfend tablets, which had U.S. sales of $81 million in the 12 months ended September and Vfend oral suspension which also generated $15.2 million during the same period.